...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
【24h】

NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.

机译:在铜绿假单胞菌中,NagZ失活可防止并恢复由AmpD和PBP 4突变驱动的β-内酰胺抗性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AmpC hyperproduction is the most frequent mechanism of resistance to penicillins and cephalosporins in Pseudomonas aeruginosa and is driven by ampD mutations or the recently described inactivation of dacB, which encodes the nonessential penicillin-binding protein (PBP) PBP 4. Recent work showed that nagZ inactivation attenuates beta-lactam resistance in ampD mutants. Here we explored whether the same could be true for the dacB mutants with dacB mutations alone or in combination with ampD mutations. The inactivation of nagZ restored the wild-type beta-lactam MICs and ampC expression of PAO1 dacB and ampD mutants and dramatically reduced the MICs (for example, the MIC for ceftazidime dropped from 96 to 4 microg/ml) and the level of ampC expression (from ca. 1,000-fold to ca. 50-fold higher than that for PAO1) in the dacB-ampD double mutant. On the other hand, nagZ inactivation had little effect on the inducibility of AmpC. The NagZ inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate attenuated the beta-lactam resistance of the AmpC-hyperproducing strains, showing a greater effect on the dacB mutant (reducing the ceftazidime MICs from 24 to 6 microg/ml) than the ampD mutant (reducing the MICs from 8 to 4 microg/ml). Additionally, nagZ inactivation in the dacB mutant blocked the overexpression of creD (blrD), which is a marker of the activation of the CreBC (BlrAB) regulator involved in the resistance phenotype. Finally, through population analysis, we show that the inactivation of nagZ dramatically reduces the capacity of P. aeruginosa to develop ceftazidime resistance, since spontaneous mutants were not obtained at concentrations > or = 8 microg/ml (the susceptibility breakpoint) for the nagZ mutant but were obtained with wild-type PAO1. Therefore, NagZ is envisaged to be a candidate target for preventing and reverting beta-lactam resistance in P. aeruginosa.
机译:AmpC过度生产是铜绿假单胞菌对青霉素和头孢菌素耐药的最常见机制,并且受ampD突变或最近描述的dacB失活的驱动,后者编码非必需的青霉素结合蛋白(PBP)PBP4。最近的研究表明,nagZ失活减弱ampD突变体中的β-内酰胺抗性。在这里,我们探讨了对于单独具有dacB突变或与ampD突变结合的dacB突变体,是否同样适用。 nagZ的失活可恢复野生型β-内酰胺MIC和PAO1 dacB和ampD突变体的ampC表达,并显着降低MIC(例如,头孢他啶的MIC从96微克/毫升降至4微克/毫升)和ampC表达水平(比PAO1高1,000倍至50倍)在dacB-ampD双突变体中。另一方面,nagZ失活对AmpC的诱导能力影响很小。 NagZ抑制剂O-(2-乙酰胺基-2-脱氧-D-吡喃吡喃并亚基)氨基-N-苯基氨基甲酸酯减弱了AmpC高产菌株的β-内酰胺抗性,显示了对dacB突变体的更大影响(降低了头孢他啶MICs比ampD突变体高24至6微克/毫升(将MIC从8至4微克/毫升降低)。另外,dacB突变体中的nagZ失活阻止了creD(blrD)的过表达,而creD是参与抗性表型的CreBC(BlrAB)调节剂激活的标志。最后,通过种群分析,我们显示nagZ的失活极大地降低了铜绿假单胞菌对头孢他啶耐药的能力,因为在nagZ突变体的浓度不大于或等于8 microg / ml(易感性断点)时,无法获得自发突变体但是是用野生型PAO1获得的。因此,NagZ被认为是预防和恢复铜绿假单胞菌中β-内酰胺抗性的候选靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号